Passage Bio (NASDAQ:PASG – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They currently have a $7.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback